The antihepatic fibrotic effects of fluorofenidone via MAPK signalling pathways

European Journal of Clinical Investigation

Volumn 43, Issue 4, 2013, Pages 358-368

  Peng, Yu ^a   Yang, Huixiang ^a   Zhu, Tingting ^a   Zhao, Menghua ^a   Deng, Yuexia ^a   Liu, Bin ^a   Shen, Hong ^a   Hu, Gaoyun ^b   Wang, Zhaohe ^c   Tao, Lijian ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c Sunshine Lake Pharma Co Ltd   (China)

Author keywords

Fluorofenidone; Hepatic fibrosis; Hepatic stellate cell; MAPK signalling pathway; PDGF BB

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA SMOOTH MUSCLE ACTIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; COLLAGEN TYPE 1; FLUOROFENIDONE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; PYRIDONE DERIVATIVE; STRESS ACTIVATED PROTEIN KINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CELL ACTIVATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER FIBROSIS; LIVER INJURY; LIVER PROTECTION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STELLATE CELL; THERAPY EFFECT; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; DIMETHYLNITROSAMINE; HEPATIC STELLATE CELLS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIVER CIRRHOSIS; MALE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 8; MODELS, ANIMAL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDONES; RANDOM ALLOCATION; RATS; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84875340329     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12053     Document Type: Article

References (40)

1. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-18.
2. Friedman SL. Liver fibrosis - from bench to bedside. J Hepatol 2003;38(Suppl. 1):38-53.
3. Friedman SL. Molecular regulation of hepatic fibrosis; an integrated cellular response to tissue injury. J Biol Chem 2000;275:2247-50.
4. Liu JY, Chen CC, Wang WH, Hsu JD, Yang MY, Wang CJ. The protective effects of Hibiscus sabdariffa extract on CCl4-induced liver fibrosis in rats. Food Chem Toxicol 2006;44:336-43.
5. Fallowfield JA, Mizuno M, Kendall TJ, Constandinou CM, Benyon RC, Duffield JS et al. Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis. J Immunol 2007;178:5288-95.
6. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T et al. Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology 2002;36:850-60.
7. Borkham-Kamphorst E, Herrmann J, Stoll D, Treptau J, Gressner A, Weiskirchen R. Dominant-negative soluble PDGF-beta receptor inhibits hepatic stellate cell activation and attenuates liver fibrosis. Lab Invest 2004;84:766-77.
8. Scharf JG, Dombrowski F, Novosyadlyy R, Eisenbach C, Demori I, Kubler B et al. Insulin-like growth factor (IGF) binding protein-1 is highly induced during acute carbon tetrachloride liver injury and potentiates the IGF-I-stimulated activation of rat hepatic stellate cells. Endocrinology 2004;145:3463-72.
9. Rachfal AW, Brigstock DR. Connective tissue growth factor (CTGF/CCN2) in hepatic fibrosis. Hepatol Res 2003;26:1-9.
10. Wang Y, Gao JC, Zhang D, Zhang J, Ma JY, Jiang HQ. New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. J Hepatol 2010;53:132-44.
11. Gentilini A, Lottini B, Brogi M, Caligiuri A, Cosmi L, Marra F et al. Evaluation of intracellular signalling pathways in response to insulin-like growth factor I in apoptotic-resistant activated human hepatic stellate cells. Fibrogenesis Tissue Repair 2009;2:1.
12. Borkham-Kamphorst E, Stoll D, Gressner AM, Weiskirchen R. Antisense strategy against PDGF B-chain proves effective in preventing experimental liver fibrogenesis. Biochem Biophys Res Commun 2004;321:413-23.
13. Seifirad S, Keshavarz A, Taslimi S, Aran S, Abbasi H, Ghaffari A. Effect of pirfenidone on pulmonary fibrosis due to paraquat poisoning in rats. Clin Toxicol 2012;50:754-8.
14. Nguyen DT, Ding C, Wilson E, Marcus GM, Olgin JE. Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias. Heart Rhythm 2010;7:1438-45.
15. RamachandraRao SP, Zhu Y, Ravasi T, McGowan TA, Toh I, Dunn SR et al. Pirfenidone is renoprotective in diabetic kidney disease. J Am Soc Nephrol 2009;20:1765-75.
16. Navarro-Partida J, Martinez-Rizo AB, Gonzalez-Cuevas J, Arrevillaga-Boni G, Ortiz-Navarrete V, Armendariz-Borunda J. Pirfenidone restricts Th2 differentiation in vitro and limits Th2 response in experimental liver fibrosis. Eur J Pharmacol 2012;678:71-7.
17. Cao W, He L, Liu W, Huang Z, Cheng Z. Determination of AKF-PD in whole blood of rat by HPLC-UV. J Chromatogr B Analyt Technol Biomed Life Sci 2006;833:257-9.
18. Tao LJ, Zhang J, Hu GY. Effects of 1-(3-fluorophenyl)-5-methyl-2-(1H) -pyridone on renal fibroblast in rats. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2004;29:139-41.
19. Xu L, Hui AY, Albanis E, Arthur MJ, O'Byrne SM, Blaner WS et al. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 2005;54:142-51.
20. Benedetti A, Di Sario A, Casini A, Ridolfi F, Bendia E, Pigini P et al. Inhibition of the Na+/H+ exchanger reduces rat hepatic stellate cell activity and liver fibrosis: an in vitro and in vivo study. Gastroenterology 2001;120:545-56.
21. Di Sario A, Bendia E, Taffetani S, Marzioni M, Candelaresi C, Pigini P et al. Selective Na+/H+ exchange inhibition by cariporide reduces liver fibrosis in the rat. Hepatology 2003;37:256-66.
22. Chevallier M, Guerret S, Chossegros P, Gerard F, Grimaud JA. A histological semi-quantitative scoring system for evaluation of hepatic fibrosis in needle liver biopsy specimens: comparison with morphometric studies. Hepatology 1994;20:349-55.
23. Pei H, Zhu H, Zeng S, Li Y, Yang H, Shen L et al. Proteome analysis and tissue microarray for profiling protein markers associated with lymph node metastasis in colorectal cancer. J Proteome Res 2007;6:2495-501.
24. Broekema M, Harmsen MC, van Luyn MJ, Koerts JA, Petersen AH, van Kooten TG et al. Bone marrow-derived myofibroblasts contribute to the renal interstitial myofibroblast population and produce procollagen I after ischemia/reperfusion in rats. J Am Soc Nephrol 2007;18:165-75.
25. Winer J, Jung CK, Shackel I, Williams PM. Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem 1999;270:41-9.
26. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008;371:838-51.
27. Fang HL, Lai JT, Lin WC. Inhibitory effect of olive oil on fibrosis induced by carbon tetrachloride in rat liver. Clin Nutr 2008;27:900-7.
28. Elsharkawy AM, Oakley F, Mann DA. The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis 2005;10:927-39.
29. Nissen NN, Martin P. Hepatocellular carcinoma: the high risk patient. J Clin Gastroenterol 2002;35:79-85.
30. Okita K, Sakaida I, Hino K. Current strategies for chemoprevention of hepatocellular carcinoma. Oncology 2002;62:24-8.
31. Lotersztajn S, Julien B, Teixeira-Clerc F, Grenard P, Mallat A. Hepatic fibrosis: molecular mechanisms and drug targets. Annu Rev Pharmacol Toxicol 2005;45:605-28.
32. Pinzani M, Milani S, Grappone C, Weber FJ, Gentilini P, Abboud HE. Expression of platelet-derived growth factor in a model of acute liver injury. Hepatology 1994;19:701-7.
33. Paik YH, Kim JK, Lee JI, Kang SH, Kim DY, Ahn SH et al. Celecoxib induces hepatic stellate cell apoptosis through inhibition of Akt activation and suppresses hepatic fibrosis in rats. Gut 2009;58:1517-27.
34. Foo NP, Lin SH, Lee YH, Wu MJ, Wang YJ. α-Lipoic acid inhibits liver fibrosis through the attenuation of ROS-triggered signaling in hepatic stellate cells activated by PDGF and TGF-β. Toxicology 2011;282:39-46.
35. Parsons CJ, Takashima M, Rippe RA. Molecular mechanisms of hepatic fibrogenesis. J Gastroenterol Hepatol 2007;22:79-84.
36. Zheng SM, Jiang MD, Zeng WZ, Xu H, Wang YX, Ma HD et al. Effects of extracellular signal-regulated kinase on rat cultured hepatic stellate cells stimulated by acetaldehyde. J Dig Dis 2007;8:148-53.
37. Garcia-Benavides L, Hernandez I, Sandoval A, Salazar A, Garcia J, Vera J et al. Pirfenidone effectively reverses experimental liver fibrosis. J Hepatol 2002;37:797-805.
38. Arthur MJ. Collagenases and liver fibrosis. J Hepatol 1995;22(Suppl. 2):43-8.
39. Olaso E, Friedman SL. Molecular regulation of hepatic fibrogenesis. J Hepatol 1998;29:836-47.
40. Wang LH, Liu JS, Ning WB, Yuan QJ, Zhang FF, Peng ZZ et al. Fluorofenidone attenuates diabetic nephropathy and kidney fibrosis in db/db mice. Pharmacology 2011;88:88-99.